Board of Directors
Julian Baines, MBE (Non-Executive Chairman)
Julian is currently Non-Executive Chairman of Trellus Health plc and Verici Dx plc, as well as being Deputy Non-Executive Chairman of EKF Diagnostics Holdings plc. Julian has significant experience in the life science industry. He has over 20 years’ experience as CEO of EKF Diagnostics Holdings plc and BBI Holdings plc. Before joining EKF, he undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. At EKF he successfully completed a number of fund raisings, acquisitions and subsequent integration of businesses in seven countries. He oversaw the spin out of businesses from EKF including Renalytix plc which listed on Nasdaq in 2020. In 2016 he was awarded an MBE (Member of the British Empire) for services to the life sciences industry. Julian has previously held the position of Non-Executive Chairman of Renalytix Plc between 2018 and 2020.
Dr. Marla Dubinsky (Chief Executive Officer and Co-Founder)
Marla Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before joining ISMMS as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children’s Hospital. She is also the Co-Director of the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally in the US and has published in 160 peer reviewed journals including Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Dr. Erik Lium, PhD (Non-Executive Director)
Erik will represent ISMMS on the Board as part of the ongoing relationship between the Company and ISMMS.
Erik is the President of Mount Sinai Innovation Partners and Executive Vice President and Chief Commercial Innovation Officer of Mount Sinai Health System, where he is responsible for advancing ISMMS’ research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialisation of technologies, and fostering the development of start-ups and joint ventures to advance promising early-stage technologies and enhance ISMMS’ research and clinical enterprises. He is a Non-executive Director of Renalytix AI plc and is chair of their audit and remuneration committees and he is also a Non-executive Director of Verici Dx plc and is chair of their remuneration committee.
Prior to joining ISMMS, Erik served as the Assistant Vice Chancellor of Innovation, Technology and Alliances at the University of California, San Francisco (UCSF), and the UCSF Principal Investigator for the Bay area National Science Foundation I-Corps node. Erik also previously served as a member of the Investment Review Committee for the Accelerate NY Seed Fund. He held previous positions at UCSF, including Assistant Vice Chancellor of Research and Director of Industry Contracts. Erik served as President of LabVelocity Inc., an Information Services Company focused on accelerating research and development in the life sciences, prior to its acquisition in 2004. He pursued post-doctoral research at UCSF in the laboratory of J. Michael Bishop, MD, and earned a PhD with honours from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein. Erik holds a BS in Biology from Gonzaga University
Mike Salter (Non-Executive Director)
Mike Salter is currently the Chief Executive officer of EKF Diagnostics Holdings plc. Previously, Mike worked at GE Healthcare where he was General Manager for the Custom Molecular Reagent Business within GE Life Sciences. He spent a total of 33 years with GE and Amersham in a variety of positions in the UK, Canada and USA.
Christopher Mills (Non-Executive Director)
Christopher Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management (“Harwood”), which he co-founded in 1993. He is Chief Executive Officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and Chairman and Chief Executive Officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, RenalytixAI plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.
Dr. Daniel Mahony (Independent Non-Executive Director, Senior Independent Director)
Dr. Daniel Mahony was appointed as Entrepreneur-in-Residence at Evotec (UK) Limited in October 2021 and is responsible for the EVOequity investment portfolio. Prior to joining Evotec, he was Co-Head of Healthcare at Polar Capital where he launched the healthcare business in 2007 growing it to over $4 billion of assets under management. Dan was formerly head of European healthcare research at Morgan Stanley, an analyst at ING Barings Furman Selz in New York and a postdoctoral scientist at DNAX Research Institute in Palo Alto.
He has over 25 years of experience within global healthcare covering biotechnology, medical technology and healthcare services Dan chairs the board of the BioIndustry Association (BIA), the industry trade association for UK life sciences, and holds non-executive directorships at the Wellcome Sanger Institute (a world leading genomics research centre), Sernova (a Canadian TSX-listed cell therapy company), Curexsys (a German privately-held biotechnology company) and Keepabl (a UK based, privately-owned provider of SaaS solutions for GDPR compliance). In 2022, he was appointed as the Life Sciences Investment Envoy by the UK Government.
Traci Entel (Non-Executive Director)
Traci has 25 years’ experience in healthcare, technology, and financial services across high-growth and large organisations as a management consultant and global HR executive. She has been a member of multiple HR leadership teams and business operating committees and has significant expertise in leading teams and advising executives on HR strategies, culture, organisational effectiveness, diversity and inclusion policies, and implementing talent strategies. Traci remains a partner at Incandescent, a New York-based management consultancy firm, where she is focused on partnering with leaders to achieve their organization, culture, and talent objectives.
Previously, as the Head of Employee Experience at Stripe and Head of Talent Management at BlackRock, Traci led the firms’ talent and culture strategies, including annual performance processes and career development, leadership development and succession, broader learning, people analytics, inclusion & diversity, and M&A. At BlackRock, she was also the lead HR Business Partner for the firm’s non-investment functions including technology, operations, institutional sales, and corporate functions. As Chief Human Capital Officer at Booz & Company, Traci developed and delivered a business-back talent strategy and led the integration with PwC to create Strategy&.
Prior to Traci’s 10 years in HR leadership roles, she worked in consulting for 14 years partnering with executives in healthcare, consumer products, and financial services. Starting her career at Mitchell Madison Group, she then spent 10 years with Katzenbach Partners, which was acquired by Booz & Company. At Booz & Company, Traci was a Partner in the firm’s Organization, Change and Leadership, and Healthcare practices where she focused on culture evolution & behavior change, talent strategy, and frontline effectiveness. She later led the people and cultural integration of Booz & Company with PwC to form Strategy&. Traci is a Partnership for New York City David Rockefeller Fellow and member of the Women’s Forum of New York.